TY - JOUR
AR - CROGR-2020-3-103
TI - Potential Novel Ovarian Cancer Treatment Targeting Myeloid-Derived Suppressor Cells
AU - Kaoru, Abiko
AU - Takuma , Hayashi
AU - Ken, Yamaguchi
AU - Masaki, Mandai
AU - Ikuo, Konishi
JO - Case Reports in Obstetrics Gynecology and Reproductive
PY - 2020
DA - Wed 30, Dec 2020
SN - 2674-5070
DO - http://dx.doi.org/10.31487/j.CROGR.2020.03.03
UR - https://www.sciencerepository.org/potential-novel-ovarian-cancer-treatment-targeting-myeloid-derived-suppressor-cells_CROGR-2020-3-103 
KW - Ovarian cancer, anti-VEGF, anti-GM-CSF, MDSC, CTL
AB - Diagnosis by biopsy is difficult in the ovary, since it is located deep in the abdomen. As a result, ovarian
cancer is mostly found insidiously during exploratory laparotomy. Consequently, early diagnosis of ovarian
cancer is often difficult. The likelihood of peritoneal dissemination increases with the progress of ovarian
cancer. With further progression, ovarian cancer metastasizes to the omentum, retroperitoneal lymph nodes,
large intestine, small intestine, diaphragm, spleen, and other organs. Ovarian cancer has been considered a
tumor that has a favourable response to chemotherapy, but more effective treatments are still being explored.
Tumors use their own immune escape mechanism to evade host immunity. The immune checkpoint (IC)
mechanism, one of the immune escape mechanisms, is established by programmed cell death-1 (PD-1)/PDligand-1 (PD-L1) communication. It has been shown that inhibiting PD-1/PD-L1 communication in various
malignancies produces antitumor effects. However, the antitumor effect of ICI monotherapy on ovarian
cancer is limited in actual clinical practice. In this review, we describe a novel cancer immunotherapeutic
agent that targets myeloid-derived suppressor cells (MDSCs).